(Q37008871)

17 August 2017

1 reference

title

Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future (English)

1 reference

17 August 2017

1 reference

2

Margaret von Mehren

1 reference

17 August 2017

Amy R MacKenzie

1

1 reference

17 August 2017

publication date

1 August 2007

1 reference

Expert Review of Anticancer Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

8

1 reference

17 August 2017

page(s)

1145-1154

1 reference

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Staging soft tissue sarcoma: evolution and change.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Carboxyl-terminal region conserved among phosphoinositide-kinase-related kinases is indispensable for mTOR function in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Dysregulation of the TSC-mTOR pathway in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Rheb fills a GAP between TSC and TOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

The LKB1 tumor suppressor negatively regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Mammalian target of rapamycin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Regulation of mTOR by phosphatidic acid?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Phosphatidic acid-mediated mitogenic activation of mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Alternative phospholipase D/mTOR survival signal in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Therapeutic targets: MTOR and related pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Mammalian target of rapamycin inhibitors in sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Is òne cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

FKBP12-Rapamycin-associated Protein (FRAP) Autophosphorylates at Serine 2481 under Translationally Repressive Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.8.1145

10.1586/14737140.7.8.1145

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference